Drug intelligence / Profile preview

ZM018

Development stage: Preclinical
Lead developer: Zumutor Biologics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ZM018 is a preclinical-stage natural killer (NK) cell therapeutic being developed by Zumutor Biologics. It is designed to target an undisclosed NK cell receptor to modulate innate immune responses, specifically aimed at treating oncological conditions. As part of Zumutor's pipeline of targeted NK cell therapies, ZM018 leverages the company's proprietary platform to enhance the anti-tumor activity of NK cells. While the specific molecular target and primary indications remain undisclosed, the therapy is positioned within the company's broader focus on immuno-oncology and innate immunity modulation.

Beyond the preview

Go deeper on ZM018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZM018.

Explore the full profile